🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Praegnant Breast Cancer: Early/Advanced/Metastatic

Recruitingn/aAges 18 Years - 99 YearsAllUniversity Hospital Tuebingen
NCT02338167 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis. Not only regard-ing therapy decisions but also with regard to quality assured healthcare and health economics this entity of patients remains a challenge. Recently, novel advances in breast cancer therapy aim at the targeted therapy of tumor entities and identification of patients, for whom the greatest therapy benefit, and the least side effects are expected. However molecular assessment of the patient and the tumor in the metastatic situation is not performed on a routine basis and in many cases tumor character-istics from the primary tumor are considered reliable enough to make therapy decisions for the metastatic patients. Although molecular reassessment of tu-mor characteristics from tumor material of the metastasis is recommended in national gu

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria for the early breast cancer setting: * Adult breast cancer patients (age ≥18 years) * Patients with breast cancer and no evidence of distant metastases with a diagnosis not longer than 91 days before study entry * Patients, who are able and willing to sign the informed consent form Inclusion Criteria for the advanced/metastatic setting: * Adult women aged ≥18 years * Patients with the diagnosis of invasive breast cancer (in German: Mammakarzinom, as op-posed to "non-invasive"= ductales Carcinoma in situ; irrespective of status of BC, e.g. TNM, re-ceptor status etc.) and * Patients, who are willing and able to sign the informed consent form * Patients with metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging) Exclusion Criteria: * Patients who did not sign the informed consent form * Patients, who are not eligible for observation due to non-availability and/or severe comor-bidities as evaluated by the treating physician
💊

What it tests

  • Blood sampling
📍

Where

61 sites
Klinikum Sindelfingen-Böblingen gGmbH
Böblingen, Germany
Klinik für Frauenheilkunde, Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
NCT Heidelberg
Heidelberg, Germany
ViDia Christliche Kliniken Karlsruhe
Karlsruhe, Germany
Praxisklinik am Rosengarten
Mannheim, Germany
medius Klinik Nürtingen
Nürtingen, Germany
Universitätsfrauenklinik Tübingen
Tübingen, Germany
Universitätsfrauenklinik Ulm
Ulm, Germany

…and 53 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy